FDA approves FluMist in expanded pediatric population
The Food and Drug Administration has approved the use of the intranasal influenza vaccine FluMist in children ages 2 to 5 years.
On September 19‚ the Food and Drug Administration (FDA) approved the use of the intranasal influenza vaccine FluMist in children ages 2 to 5 years. The vaccine was previously approved for children ages 5 years and older.
“This approval offers parents and health professionals a needle-free option for squeamish toddlers‚ who may be reluctant to get a traditional influenza shot,” said Jesse L. Goodman‚ MD‚ director‚ of FDA’s Center for Biologics Evaluation and Research.
According to the FDA‚ only two flu vaccines had been previously licensed for use in the US for children under 5. FluMist should not be given to anyone with asthma‚ or to children under the age of 5 with recurrent wheezing‚ due to the potential of increased wheezing after vaccine administration.
Comparison of teen- and parent-reported estimates of social and emotional support, 2021 to 2022
July 23rd 2024The investigative team noted that teenagers with emotional and social support are better off to handle stressors such as biological and social transition, and are less likely to experience a variety of adverse physical and mental health outcomes.
